Saffron Walden, UK, 30 March 2017/
30th March 2017
7th March 2017
Domainex launched its fragment screening service, FragmentBuilder at a drug discovery meeting and is UK’s first CRO to offer MicroScale Thermophoresis (MST).
15th December 2016
Saffron Walden, UK, 15th December 2016 / Domainex Ltd announces today that it has purchased and fully commissioned a Monolith NT.Automated instrument from NanoTemper Technologies Ltd.
17th November 2016
Saffron Walden, UK, 17th November 2016 / Saffron Walden, UK, 17th November 2016 / Sir Simon Campbell, CBE FRS FMedSci, was welcomed by staff and guests when he officially opened The Domainex Medicines Research Centre on Friday 11th November 2016.
12th September 2016
Saffron Walden, UK, 12th September 2016 / Established in 2001, Domainex is a privately-owned, rapidly-growing drug research company with expertise in expression of disease target proteins, hit discovery, hit-to-lead identification and lead optimisation.
26th April 2016
Queen’s University Belfast and Domainex Ltd secure funding from the Wellcome Trust to accelerate early development of first-in-class FLIP inhibitors.
19th April 2016
Johnson Matthey and Domainex have announced a collaboration to provide integrated small molecule pharmaceutical discovery and development services.
3rd February 2016
Latest winner of Domainex Discovery STAR Award is Dr Aude Echalier, Lecturer in Structural Biology of Cancer Related Targets at the University of Leicester.
25th January 2016
Domainex Ltd. and Cresset Discovery Services, today announced an alliance to provide their customers with world-class laboratory-based and computational drug discovery services through a seamless combination of their respective capabilities in chemistry and biology.
15th December 2015
A new £3.4 million programme will develop new tools to understand which interactions between proteins in the human body are relevant to disease.